Posted On: 10/28/2015 7:05:12 AM
Post# of 30066
@G_Commish: To those asking: Yes, we are pushing forward with our plans for ESS clinical trial preparation & Dx transaction for this quarter. $AMBS
@@G_Commish: @G_Commish I will provide a formal program update next week via blog. ESS remains our primary focus heading into JP Morgan 2016.
$AMBSG_Commish: @G_Commish Good Board of Directors meeting yesterday. Tomorrow is our Dx strategy session with Dx MS and AD leadership in Dallas. $AMBS
@G_Commish: @G_Commish Nothing fundamental has occurred to our programs that justifies the recent share price decline. $AMBS
@G_Commish: @G_Commish We have seen declines like this in the past and overcame them. We are working hard in hopes that history repeats itself. $AMBS
@G_Commish: @G_Commish The fundamentals of our pipeline and near-term value milestones are immensely stronger now than they were in Q4/2012. $AMBS
@@G_Commish: @G_Commish I will provide a formal program update next week via blog. ESS remains our primary focus heading into JP Morgan 2016.
$AMBSG_Commish: @G_Commish Good Board of Directors meeting yesterday. Tomorrow is our Dx strategy session with Dx MS and AD leadership in Dallas. $AMBS
@G_Commish: @G_Commish Nothing fundamental has occurred to our programs that justifies the recent share price decline. $AMBS
@G_Commish: @G_Commish We have seen declines like this in the past and overcame them. We are working hard in hopes that history repeats itself. $AMBS
@G_Commish: @G_Commish The fundamentals of our pipeline and near-term value milestones are immensely stronger now than they were in Q4/2012. $AMBS
(0)
(0)
